{"id":"ufh","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Bleeding"},{"rate":"1-5%","effect":"Hypersensitivity reactions"},{"rate":"null","effect":"Osteoporosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"UFH is a heparin-based anticoagulant that works by binding to antithrombin III, which in turn inhibits the activity of Factor Xa and thrombin. This leads to a decrease in the formation of blood clots and an increase in the breakdown of existing clots.","oneSentence":"UFH acts as an anticoagulant by inhibiting the coagulation cascade, specifically by inactivating Factor Xa and thrombin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:09.036Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism"},{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT04790370","phase":"PHASE4","title":"Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2021-08-02","conditions":"Pulmonary Embolism","enrollment":544},{"nctId":"NCT05848713","phase":"PHASE3","title":"AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia","status":"RECRUITING","sponsor":"University of Manitoba","startDate":"2023-10-10","conditions":"Community-acquired Pneumonia","enrollment":4000},{"nctId":"NCT07352800","phase":"PHASE2","title":"Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia","status":"RECRUITING","sponsor":"Aplagon Oy","startDate":"2026-01-29","conditions":"Peripheral Arterial Occlusive Disease, Chronic Limb-Threatening Ischemia","enrollment":42},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT07361783","phase":"NA","title":"Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI 2 Trial","status":"RECRUITING","sponsor":"Chen Jing","startDate":"2025-08-13","conditions":"Primary PCI, ST-elevation Myocardial Infarction (STEMI)","enrollment":6294},{"nctId":"NCT07302620","phase":"","title":"HEPARINS: INTERFERENCE IN ARGATROBAN MEASUREMENT","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2024-12-03","conditions":"Thromboembolic Disease","enrollment":70},{"nctId":"NCT07246018","phase":"","title":"Accuracy and Reliability of Artificial Intelligence Cephalometric Analysis Software Compared to Manual Tracing","status":"COMPLETED","sponsor":"International Islamic University Malaysia","startDate":"2023-01-02","conditions":"Cephalometry, Orthodontic, Cephalometric Analysis","enrollment":40},{"nctId":"NCT05684796","phase":"NA","title":"Comparison of Two Pulmonary Embolism Treatments","status":"COMPLETED","sponsor":"Penumbra Inc.","startDate":"2023-11-27","conditions":"Pulmonary Embolism Acute","enrollment":100},{"nctId":"NCT04545541","phase":"PHASE2, PHASE3","title":"Nebulised Heparin in Patients With Severe COVID-19","status":"COMPLETED","sponsor":"Australian National University","startDate":"2020-11-01","conditions":"Covid19, Respiratory Failure","enrollment":57},{"nctId":"NCT07214103","phase":"PHASE2","title":"Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-03-01","conditions":"Septic Shock, Coagulopathy","enrollment":120},{"nctId":"NCT06517563","phase":"PHASE1","title":"Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin","status":"ACTIVE_NOT_RECRUITING","sponsor":"VarmX B.V.","startDate":"2024-08-14","conditions":"Coagulation Disorder","enrollment":16},{"nctId":"NCT04049591","phase":"NA","title":"Higher vs. Lower Dose Heparin for PCI","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2022-03-02","conditions":"Cardiovascular Diseases, Percutaneous Coronary Intervention","enrollment":16000},{"nctId":"NCT07032025","phase":"EARLY_PHASE1","title":"Mechanical Thrombectomy for Acute Pulmonary Embolism","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-07-01","conditions":"Acute Pulmonary Embolism","enrollment":200},{"nctId":"NCT04924322","phase":"PHASE2, PHASE3","title":"Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies","status":"RECRUITING","sponsor":"Yale University","startDate":"2022-05-11","conditions":"Deep Venous Thrombosis","enrollment":258},{"nctId":"NCT06868823","phase":"","title":"Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation","status":"RECRUITING","sponsor":"University Hospital, Motol","startDate":"2025-05-01","conditions":"Lung Transplantation, Extracorporeal Membrane Oxygenation (ECMO), Anticoagulants and Bleeding Disorders","enrollment":40},{"nctId":"NCT05247424","phase":"PHASE4","title":"Pretreatment With Unfractionated Heparin for ST Elevation Myocardial Infarction","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2022-03-10","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":600},{"nctId":"NCT05204550","phase":"PHASE2, PHASE3","title":"Intranasal Heparin Treatment to Reduce Transmission Among Household Contacts of COVID 19 Positive Adults and Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2023-01-30","conditions":"COVID-19","enrollment":506},{"nctId":"NCT05726825","phase":"NA","title":"Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic Shock","status":"RECRUITING","sponsor":"Hannover Medical School","startDate":"2025-02-19","conditions":"Septic Shock","enrollment":274},{"nctId":"NCT06010446","phase":"","title":"Intravenous Continuous LMWH Seems to Be Safe Alternative to UFH in VV ECMO Patients","status":"COMPLETED","sponsor":"University Hospital, Motol","startDate":"2019-05-15","conditions":"Refractory Respiratory Failure","enrollment":43},{"nctId":"NCT05208112","phase":"PHASE1","title":"Intravenously Administered M6229 in Critically Ill Sepsis Patients","status":"COMPLETED","sponsor":"A.P.J. Vlaar","startDate":"2022-04-05","conditions":"Sepsis, Septic Shock, Critical Illness","enrollment":10},{"nctId":"NCT04362085","phase":"PHASE3","title":"Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2020-05-11","conditions":"COVID-19","enrollment":465},{"nctId":"NCT06779162","phase":"","title":"ROTEM-based Optimization of Anticoagulation Regimens in Lung Transplantation","status":"COMPLETED","sponsor":"University Hospital, Motol","startDate":"2022-01-01","conditions":"Anticoagulation, Lung Transplantation, Viscoelastic Properties","enrollment":65},{"nctId":"NCT05305612","phase":"PHASE4","title":"Optimal PeriproCeduraL AnticOagulation in Structural Transseptal Interventions","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2022-03-13","conditions":"Mitral Regurgitation, Atrial Fibrillation, Anticoagulation","enrollment":410},{"nctId":"NCT06222866","phase":"","title":"Anticoagulation and Inflammation Monitoring in Patients After Heart and Vascular Interventions","status":"RECRUITING","sponsor":"Medical University Innsbruck","startDate":"2024-06-25","conditions":"Heart Surgery, Vascular Surgery, Delirium","enrollment":400},{"nctId":"NCT04088292","phase":"PHASE3","title":"Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2019-06-06","conditions":"Pulmonary Embolism","enrollment":210},{"nctId":"NCT06442267","phase":"PHASE4","title":"Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-07-30","conditions":"Respiratory Insufficiency, Circulatory Failure, Thromboembolism","enrollment":90},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06487052","phase":"NA","title":"Evaluation of the Standard Catheter-directed Thrombolysis Effectiveness in Intermediate-High-Risk Pulmonary Embolism Patients","status":"RECRUITING","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2024-01-10","conditions":"Pulmonary Embolism Acute","enrollment":100},{"nctId":"NCT05148026","phase":"NA","title":"Regional Citrate Anticoagulation for RRT During V-V ECMO","status":"RECRUITING","sponsor":"University of Milano Bicocca","startDate":"2021-11-14","conditions":"ARDS, Human, Acute Kidney Injury","enrollment":20},{"nctId":"NCT06375616","phase":"PHASE4","title":"Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI","status":"NOT_YET_RECRUITING","sponsor":"Shen Lei","startDate":"2024-04","conditions":"Sepsis","enrollment":156},{"nctId":"NCT04925167","phase":"NA","title":"Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO","status":"COMPLETED","sponsor":"Beijing Chao Yang Hospital","startDate":"2021-07-06","conditions":"Respiratory Failure","enrollment":20},{"nctId":"NCT04561648","phase":"NA","title":"Standard vs High Dose of Unfractionated Heparin in the Incidence of Radial Artery Occlusion (DEFINITION) Trial.","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2020-08-01","conditions":"Radial Artery Occlusion","enrollment":1988},{"nctId":"NCT04409834","phase":"PHASE4","title":"Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial","status":"COMPLETED","sponsor":"The TIMI Study Group","startDate":"2020-08-05","conditions":"COVID-19, Venous Thromboembolism, Arterial Thrombosis","enrollment":390},{"nctId":"NCT03083184","phase":"PHASE3","title":"Evaluation of the Efficacy of an inTerdialytic \"Ethanol 40% v/v - enoxapaRin 1000 U/mL\" Lock solutioN to Prevent Tunnelled Catheter Infections in Chronic Hemodialysis Patients","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2018-02-09","conditions":"Tunnelled Hemodialysis Catheter Infection","enrollment":400},{"nctId":"NCT05143567","phase":"NA","title":"Hemostasis and Inflammation in COVID-19 Patients With Venous and Arterial Thrombotic Complications","status":"COMPLETED","sponsor":"Ryazan State Medical University","startDate":"2021-11-01","conditions":"Venous Thromboembolism, covid19, Thrombosis","enrollment":150},{"nctId":"NCT06054997","phase":"","title":"Anaesthesiologic Considerations for Intraoperative ECMO Anticoagulation During Lung Transplantation","status":"COMPLETED","sponsor":"University Hospital, Motol","startDate":"2020-01-01","conditions":"Lung Transplantation","enrollment":141},{"nctId":"NCT04406389","phase":"PHASE4","title":"Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2020-10-13","conditions":"COVID-19","enrollment":14},{"nctId":"NCT05022563","phase":"","title":"Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-31","conditions":"Venous Thromboembolism","enrollment":55759},{"nctId":"NCT04569279","phase":"PHASE3","title":"Rivaroxaban vs. Warfarin in CVT Treatment","status":"COMPLETED","sponsor":"Damascus University","startDate":"2017-09-01","conditions":"Cerebral Vein Thrombosis","enrollment":71},{"nctId":"NCT05671250","phase":"PHASE2","title":"Bioactive Smart Dressings for Diabetic Foot Ulcers: Randomized Controlled Trial","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2021-07-15","conditions":"Diabetic Foot Ulcer","enrollment":30},{"nctId":"NCT05237726","phase":"NA","title":"Efficacy and Safety for Different Regimen of VTE Pharmacoprophylaxis Among Severely Burn Patients","status":"COMPLETED","sponsor":"King Abdullah International Medical Research Center","startDate":"2020-04-05","conditions":"Burns","enrollment":20},{"nctId":"NCT03568838","phase":"PHASE4","title":"Prolonged Enoxaparin in Primary Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2018-06-28","conditions":"Myocardial Infarction","enrollment":100},{"nctId":"NCT02664155","phase":"PHASE3","title":"Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2016-10-19","conditions":"Renal Insufficiency","enrollment":203},{"nctId":"NCT01442792","phase":"PHASE2","title":"Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-10-12","conditions":"Cardiovascular Disease, Coronary Artery Disease","enrollment":108},{"nctId":"NCT03378466","phase":"PHASE2","title":"Heparin Anticoagulation in Septic Shock","status":"TERMINATED","sponsor":"University of Manitoba","startDate":"2018-03-12","conditions":"Septic Shock, Vasodilatory Shock","enrollment":178},{"nctId":"NCT04600141","phase":"PHASE3","title":"Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2020-11-10","conditions":"Covid19","enrollment":308},{"nctId":"NCT04377997","phase":"PHASE2","title":"Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2020-05-15","conditions":"Cardiovascular Diseases, COVID-19","enrollment":300},{"nctId":"NCT02144064","phase":"PHASE3","title":"Pregnancy Outcomes in Women With Unexplained Recurrent Pregnancy Loss Treated With Low Dose Aspirin and Unfractionated Heparin","status":"UNKNOWN","sponsor":"Benha University","startDate":"2019-06-23","conditions":"Recurrent Pregnancy Loss","enrollment":200},{"nctId":"NCT04357730","phase":"PHASE2","title":"Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection","status":"COMPLETED","sponsor":"Denver Health and Hospital Authority","startDate":"2020-05-14","conditions":"Severe Acute Respiratory Syndrome, Respiratory Failure, Acute Respiratory Distress Syndrome","enrollment":50},{"nctId":"NCT04416048","phase":"PHASE2","title":"Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2020-11-30","conditions":"COVID-19","enrollment":111},{"nctId":"NCT05148377","phase":"PHASE3","title":"UFH is the Most Used Anticoagulant in Hemodialysis, Decreasing the Risk of Clot Formation in the Circuit.","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2007-08-01","conditions":"Hemodialysis Complication","enrollment":128},{"nctId":"NCT04401293","phase":"PHASE3","title":"Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2020-04-26","conditions":"Sars-CoV2, COVID","enrollment":257},{"nctId":"NCT04444700","phase":"PHASE3","title":"A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-07-04","conditions":"COVID, Coronavirus Infection, Severe Acute Respiratory Syndrome","enrollment":465},{"nctId":"NCT04372589","phase":"PHASE2, PHASE3","title":"Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)","status":"COMPLETED","sponsor":"University of Manitoba","startDate":"2020-05-20","conditions":"COVID-19, Pneumonia","enrollment":1200},{"nctId":"NCT04528888","phase":"PHASE3","title":"Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection","status":"UNKNOWN","sponsor":"Massimo Girardis","startDate":"2020-11-25","conditions":"Covid19, SARS-CoV Infection, Pneumonia, Viral","enrollment":210},{"nctId":"NCT04782843","phase":"","title":"Evaluation of the Intra-observer Agreement of the HEP Score in Surgical Intensive Care.","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2021-03-01","conditions":"Heparin-induced Thrombocytopenia","enrollment":124},{"nctId":"NCT04708080","phase":"","title":"Effects of Thoracic Epidural Analgesia in Geriatric Patients Undergoing Open Heart Surgery","status":"COMPLETED","sponsor":"Karadeniz Technical University","startDate":"2020-07-01","conditions":"Epidural Analgesia, Mechanical Ventilation, Postoperative Complications","enrollment":640},{"nctId":"NCT03000673","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-05-23","conditions":"Antithrombotic","enrollment":32},{"nctId":"NCT04042324","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2019-09-30","conditions":"End Stage Renal Disease","enrollment":12},{"nctId":"NCT02974660","phase":"PHASE4","title":"Protamine Sulfate During Transcatheter Aortic Valve Implantation","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2016-12","conditions":"Aortic Valve Stenosis","enrollment":100},{"nctId":"NCT04445935","phase":"PHASE4","title":"Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial","status":"UNKNOWN","sponsor":"Hamad Medical Corporation","startDate":"2020-06-28","conditions":"Anticoagulation in COVID-19 ARDS","enrollment":100},{"nctId":"NCT02934997","phase":"","title":"The Role of Dysfunctional HDL in Sepsis","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-11-01","conditions":"Sepsis, Septic Shock","enrollment":88},{"nctId":"NCT03244319","phase":"PHASE3","title":"Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial)","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2017-12-01","conditions":"MV(Mitral Valve) Repair","enrollment":220},{"nctId":"NCT04121611","phase":"NA","title":"Optical Coherence Tomography Guided Antithrombotic Treatment After Endovascular Thrombectomy of the Posterior Circulation","status":"UNKNOWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2019-10-14","conditions":"Stroke of Basilar Artery, Optical Coherence Tomography, Antithrombotics","enrollment":25},{"nctId":"NCT00543400","phase":"PHASE2","title":"Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)","status":"COMPLETED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2007-09","conditions":"Coronary Artery Disease (CAD)","enrollment":503},{"nctId":"NCT04063423","phase":"","title":"Non- Clinical Coagulation Activation During Hemodialysis","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2018-10-25","conditions":"Kidney Diseases, End Stage Renal Disease, Hemodialysis Complication","enrollment":32},{"nctId":"NCT02098993","phase":"PHASE2","title":"Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome","status":"TERMINATED","sponsor":"Craig Seaman","startDate":"2014-05","conditions":"Acute Chest Syndrome, Sickle Cell Disease","enrollment":7},{"nctId":"NCT01378000","phase":"","title":"Study on Continuous Intravenous of Unfractionated Heparin (UFH) to Treat Progressive Cerebral Infarction","status":"COMPLETED","sponsor":"Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine","startDate":"2009-10","conditions":"Heparin Causing Adverse Effects in Therapeutic Use, Heparin-induced Thrombosis, Acute Cerebral Ischemia","enrollment":480},{"nctId":"NCT03753048","phase":"NA","title":"Total Arterial Revascularization (TAR)","status":"UNKNOWN","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2018-03-13","conditions":"Coronary Artery Disease, Coronary Artery Bypass Grafting","enrollment":880},{"nctId":"NCT02565147","phase":"PHASE3","title":"Bivalirudin Infusion for Ventricular Infarction Limitation","status":"TERMINATED","sponsor":"The Medicines Company","startDate":"2014-12-19","conditions":"Acute Myocardial Infarction","enrollment":78},{"nctId":"NCT02506985","phase":"PHASE4","title":"XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis","status":"TERMINATED","sponsor":"Susan Smyth","startDate":"2015-07","conditions":"Pulmonary Embolism, Venous Thrombosis","enrollment":10},{"nctId":"NCT02767232","phase":"PHASE3","title":"Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2018-07","conditions":"Deep Vein Thrombosis, Post-Thrombotic Syndrome, Venous Thrombosis","enrollment":""},{"nctId":"NCT00182403","phase":"PHASE3","title":"Fixed Dose Heparin Study","status":"COMPLETED","sponsor":"McMaster University","startDate":"1998-09","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism","enrollment":866},{"nctId":"NCT01913483","phase":"PHASE3","title":"ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial","status":"TERMINATED","sponsor":"The Medicines Company","startDate":"2013-09-24","conditions":"Peripheral Endovascular Interventions, Bleeding","enrollment":732},{"nctId":"NCT02707263","phase":"NA","title":"Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2016-03","conditions":"Venous Thromboembolism","enrollment":""},{"nctId":"NCT01651780","phase":"PHASE3","title":"Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2012-10","conditions":"Severe Aortic Stenosis, Transcatheter Aortic Valve Replacement, Aortic Valve Replacement","enrollment":803},{"nctId":"NCT00790907","phase":"PHASE4","title":"Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Acute Coronary Syndrome","enrollment":3235},{"nctId":"NCT00257309","phase":"PHASE4","title":"Thrombolysis Versus Primary Angioplasty for AMI in Elderly Patients","status":"TERMINATED","sponsor":"Spanish Society of Cardiology","startDate":"2005-04","conditions":"Acute Myocardial Infarction","enrollment":266},{"nctId":"NCT00981409","phase":"PHASE3","title":"The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07","conditions":"Embolism, Pulmonary","enrollment":41},{"nctId":"NCT00911157","phase":"PHASE3","title":"The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06","conditions":"Thrombosis, Venous","enrollment":39},{"nctId":"NCT02957877","phase":"PHASE4","title":"LMWH Infusion as Anticoagulation for Home HD","status":"UNKNOWN","sponsor":"Alice Ho Miu Ling Nethersole Hospital","startDate":"2016-03","conditions":"Endstage Renal Disease","enrollment":12},{"nctId":"NCT00064428","phase":"PHASE3","title":"OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-08","conditions":"Thromboembolism","enrollment":12092},{"nctId":"NCT01780987","phase":"PHASE3","title":"AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-01","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":80},{"nctId":"NCT02763839","phase":"PHASE1","title":"Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2001-04","conditions":"Parkinson's Disease","enrollment":19},{"nctId":"NCT02763852","phase":"PHASE1","title":"Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2001-04","conditions":"Parkinson's Disease","enrollment":18},{"nctId":"NCT01076764","phase":"PHASE3","title":"Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-04","conditions":"Acute Coronary Syndrome","enrollment":13220},{"nctId":"NCT02091479","phase":"PHASE3","title":"Early Versus Late Resumption of Anticoagulation in Patients With Both High Thrombosis Risk and Major HEmoRrhage","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2013-01","conditions":"Major hæmorrhage","enrollment":14},{"nctId":"NCT02698618","phase":"PHASE4","title":"PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor","status":"UNKNOWN","sponsor":"Fundacion Investigacion Interhospitalaria Cardiovascular","startDate":"2016-03","conditions":"Diabetes Mellitus, Type 2","enrollment":50},{"nctId":"NCT01087723","phase":"PHASE3","title":"European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2010-03","conditions":"Acute Coronary Syndrome","enrollment":2198},{"nctId":"NCT01855516","phase":"NA","title":"Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2013-09","conditions":"Thrombosis","enrollment":83},{"nctId":"NCT01070875","phase":"NA","title":"Partial Thromboplastin Time During the First 24 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin (UFH)","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2010-04","conditions":"Thrombosis","enrollment":53},{"nctId":"NCT00616460","phase":"PHASE3","title":"ACRIPAB- Trial: Anti Coagulation Regimen In High Risk PAtients for Bleeding","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2008-02","conditions":"Hematologic Diseases","enrollment":100},{"nctId":"NCT01519518","phase":"PHASE4","title":"How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Liverpool Heart and Chest Hospital NHS Foundation Trust","startDate":"2012-02","conditions":"Acute ST Elevation Myocardial Infarction","enrollment":1829},{"nctId":"NCT02052544","phase":"","title":"Clinical Performance Evaluation of Pefakit® PiCT® UC In Vitro Diagnostic Medical Device","status":"COMPLETED","sponsor":"dsm-firmenich Switzerland AG","startDate":"2012-04","conditions":"Thromboembolic Events","enrollment":123},{"nctId":"NCT01433627","phase":"PHASE3","title":"Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX","status":"UNKNOWN","sponsor":"Italian Society of Invasive Cardiology","startDate":"2011-10","conditions":"Acute Coronary Syndromes, STEMI, NSTEMI","enrollment":7200},{"nctId":"NCT00317395","phase":"PHASE2","title":"Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Coronary Disease","enrollment":3241},{"nctId":"NCT02294994","phase":"PHASE4","title":"Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease","status":"UNKNOWN","sponsor":"Second Hospital of Jilin University","startDate":"2014-11","conditions":"Coronary Artery Disease","enrollment":1000},{"nctId":"NCT02181998","phase":"PHASE3","title":"A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-07","conditions":"Myocardial Infarction","enrollment":1606},{"nctId":"NCT01465503","phase":"PHASE3","title":"Novel Approaches in Preventing and Limiting Events III Trial (NAPLES III): Bivalirudin in High-risk Bleeding Patients","status":"COMPLETED","sponsor":"Clinica Mediterranea","startDate":"2008-01","conditions":"Bleeding","enrollment":837},{"nctId":"NCT01956955","phase":"PHASE4","title":"Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism","status":"UNKNOWN","sponsor":"Ataturk University","startDate":"2011-01","conditions":"This Study Will Provide Data Comparing Safety of LMWH Versus UFH in the Treatment of Acute PE Cases Who Require Thrombolytic Treatment.","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2850,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Unfractionated Heparin"],"phase":"phase_3","status":"active","brandName":"UFH","genericName":"UFH","companyName":"VarmX B.V.","companyId":"varmx-b-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"UFH acts as an anticoagulant by inhibiting the coagulation cascade, specifically by inactivating Factor Xa and thrombin. Used for Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism, Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}